Therefore, inhibiting the axis between cancer and immune cells through antibodies directed at CTLA-4/PD-1 leads to the invaluable improvement in treatment efficacy of numerous malignant tumors especially melanoma, lung cancer, and breast cancer [6,31]. This evidence concerns the gene PDCD1 and lung carcinoma.